GLP1R and metabolic dysfunction-associated steatohepatitis: Regarding clinical studies, in a phase II 48-week randomized controlled trial, the GLP-1R agonist liraglutide induced resolution of NASH in both diabetic and nondiabetic patients, as well as improved steatosis and ballooning17.